Phase 3 ADAURA Study Highlights Role for Precision Medicine in EGFR-Positive NSCLC
Masahiro Tsuboi, MD, discusses the findings from the phase 3 ADAURA clinical trial of osimertinib as treatment of patients with EGFR-mutated non–small cell lung cancer.
Masahiro Tsuboi, MD, a surgeon at the National Cancer Center Hospital East in Japan, discusses the findings from the phase 3 ADAURA clinical trial of osimertinib (Tagrisso) as treatment of patients with EGFR-mutated non–small cell lung cancer (NSCLC).
In terms of safety, the adverse event (AE) profile was consistent with the known profile of osimertinib, the EGFR tyrosine kinase inhibitor. The most common AEs were primarily grades 1 or 2, and the incidence of grade 3 AEs was low with osimertinib, according to Tsuboi.
Osimertinib induced a highly significant and clinically meaningful improvement in disease-free survival and reduced the risk of distant recurrence. The disease-free survival was especially notable in the population of patients with completed resected stage 1/2b/3a EGFR-mutant NSCLC. Tsuboi says he has observed a wave if precision medicine in the post-operative space.
Amivantamab/Lazertinib Shows OS and PFS Benefits in EGFR-Mutated NSCLC
April 21st 2025During a live event, Xiuning Le, MD, PhD, discussed updated intracranial efficacy, overall survival, and safety of amivantamab plus lazertinib in patients with EGFR-mutated non–small cell lung cancer.
Read More
